Moderna’s COVID-19 and Flu Vaccine Approval Delayed: What You Need to Know for 2026 Frank Dolan May 2, 2025
Bristol Myers Squibb Shuts Down Chicago Viral Vector Production Site Amid Cost-Cutting Strategy Frank Dolan May 1, 2025
Teladoc Health Expands Mental Health Solutions with UpLift Acquisition for $30 Million Frank Dolan May 1, 2025
Novartis Acquires Regulus Therapeutics for $800M: A Bold Move to Revolutionize ADPKD Treatment Frank Dolan May 1, 2025
Regeneron Faces Legal Challenges: Court Allows DOJ Lawsuit Over Eylea Medicare Fraud to Proceed Frank Dolan April 30, 2025
Noma Therapy Secures $4.25M for Pioneering Virtual Ketamine-Assisted Mental Health Solutions Frank Dolan April 30, 2025
Is Liquidation the Best Move for Acelyrin? How Shareholder Pressure is Shifting Biotech Strategies! Frank Dolan April 30, 2025
Join the Conversation: Endpoints News Launches ‘Post-Hoc Live!’ to Explore Pharma’s ‘Liberation Day’ Response Frank Dolan April 29, 2025
FDA Delays Key Drug Decision: Is Trump-Era Budget Cuts Impacting Biotech Innovation? Frank Dolan April 29, 2025
Novavax Stays Optimistic as FDA Requests Additional Studies for COVID Vaccine Approval Frank Dolan April 29, 2025
Vaxart’s Next-Gen Covid-19 Vaccine: Major Breakthrough as Stop-Work Order Lifted for Mid-Stage Trials Frank Dolan April 28, 2025
Keytruda’s Breakthrough: New Hope in Head and Neck Cancer Surgery with Pre- and Post-Operative Use Frank Dolan April 28, 2025
Promising Breakthrough: Johnson & Johnson’s ‘Pretzel’ Drug Shows 45% Success in Bladder Cancer Treatment! Frank Dolan April 27, 2025
Key Earnings Insights: Pharma Giants Navigate Tariff Pressures, AkeÂso’s Promising Data, and a CRISPR Breakthrough Frank Dolan April 26, 2025
Biohaven Pharmaceuticals Faces $400 Million Stock Plunge After Dazluma Marketing Setback: What’s Next? Frank Dolan April 26, 2025
Amgen Invests $900 Million to Boost Biomanufacturing in Ohio: A Response to U.S. Pharma Trends Frank Dolan April 25, 2025
Gilead Sciences’ HIV Drug Sales Surge in Q1 2025 Amidst Challenges in Covid-19 and Cancer Markets Frank Dolan April 25, 2025
Bristol Myers Squibb’s Cobenfy: A Game Changer for Schizophrenia Treatment with $27 Million Launch Success! Frank Dolan April 25, 2025
How Trump’s Tariffs Are Shaping the Future of the Pharmaceutical Industry: Insights from Major Players Frank Dolan April 24, 2025
AstraZeneca’s CEO Urges Europe to Boost Investment in Drug R&D for Health Sovereignty Frank Dolan April 24, 2025